These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25556893)

  • 1. Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes.
    Iizuka M; Nakanishi Y; Fuchinoue F; Maeda T; Murakami E; Obana Y; Enomoto K; Tani M; Sakurai K; Amano S; Masuda S
    Cancer Sci; 2015 Mar; 106(3):307-14. PubMed ID: 25556893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
    Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
    Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.
    Siroy A; Abdul-Karim FW; Miedler J; Fong N; Fu P; Gilmore H; Baar J
    Hum Pathol; 2013 Oct; 44(10):2159-66. PubMed ID: 23845471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
    Sinn BV; von Minckwitz G; Denkert C; Eidtmann H; Darb-Esfahani S; Tesch H; Kronenwett R; Hoffmann G; Belau A; Thommsen C; Holzhausen HJ; Grasshoff ST; Baumann K; Mehta K; Dietel M; Loibl S
    Ann Oncol; 2013 Sep; 24(9):2316-24. PubMed ID: 23661292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
    Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
    Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.
    Dennison JB; Shahmoradgoli M; Liu W; Ju Z; Meric-Bernstam F; Perou CM; Sahin AA; Welm A; Oesterreich S; Sikora MJ; Brown RE; Mills GB
    Clin Cancer Res; 2016 Oct; 22(20):5068-5078. PubMed ID: 27172895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
    Bae MS; Seo M; Kim KG; Park IA; Moon WK
    Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
    Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
    Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.